EBITDA: Income before interest, taxes, depreciation and amortization.
Parabilis Medicines, Inc. (PBLS) had EBITDA of $-50.50M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.15M |
|
$-66.95M |
|
-- |
|
$0.15M |
|
$51.03M |
|
$-50.89M |
|
$-1.58M |
|
$-52.46M |
|
$-52.46M |
|
$-52.46M |
|
$-52.46M |
|
$-52.46M |
|
$-52.46M |
|
$-50.89M |
|
|
EBITDA |
$-50.50M |
28.91M |
|
28.91M |
|
$-2.32 |
|
$-2.32 |
|
| Balance Sheet Financials | |
$1.13B |
|
$6.72M |
|
$49.87M |
|
$1.18B |
|
$62.84M |
|
$1.13M |
|
$64.69M |
|
$127.53M |
|
$1.05B |
|
$1.05B |
|
$1.05B |
|
123.52M |
|
| Cash Flow Statement Financials | |
$-52.82M |
|
$-34.43M |
|
$1.15B |
|
$30.57M |
|
$1.09B |
|
$1.06B |
|
$4.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.91 |
|
-- |
|
-- |
|
0.00 |
|
0.01 |
|
100.00% |
|
-34382.43% |
|
-34382.43% |
|
-- |
|
-35447.97% |
|
-45239.86% |
|
$-53.81M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.01% |
|
-5.01% |
|
-4.46% |
|
-5.00% |
|
$8.48 |
|
$-1.86 |
|
$-1.83 |
|